Ipilimumab/Nivolumab Is the New Standard of Care in Metastatic Renal Cell Carcinoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [1] Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care
    Nizam, Amanda
    Aragon-Ching, Jeanny B.
    CANCER BIOLOGY & THERAPY, 2019, 20 (01) : 6 - 7
  • [2] Nivolumab and Ipilimumab in Renal Cell Carcinoma
    Alakus, Hakan
    Zander, Thomas
    Bruns, Christiane
    ONKOLOGE, 2018, 24 (06): : 500 - 504
  • [3] Sunitinib—a new standard of care for metastatic renal cell carcinoma
    Walter M Stadler
    Russell Z Szmulewitz
    Nature Clinical Practice Oncology, 2007, 4 : 458 - 459
  • [4] Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
    Savarapu, Pramod
    Abdelazeem, Basel
    Isa, Sakiru
    Kesari, Kavitha
    Kunadi, Arvind
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2021, 11 (06): : 874 - 876
  • [5] Sunitinib - a new standard of care for metastatic renal cell carcinoma
    Stadler, Walter M.
    Szmulewitz, Russell Z.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (08): : 458 - 459
  • [6] Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
    Segawa, Takuya
    Motoshima, Takanobu
    Yatsuda, Junji
    Kurahashi, Ryoma
    Fukushima, Yumi
    Murakami, Yoji
    Yamaguchi, Takahiro
    Sugiyama, Yutaka
    Yoshida, Ryoji
    Nakayama, Hideki
    Kamba, Tomomi
    IJU CASE REPORTS, 2023, 6 (02) : 147 - 149
  • [7] SUNNIFORECAST - A phase II study of Nivolumab in combination with Ipilimumab versus Standard of care in advanced or metastatic non-clear cell renal cell carcinoma
    Scheich, S.
    Ahrens, M.
    Goekbuget, N.
    Boleti, E.
    Burkholder, I
    Escudier, B. J.
    Goebell, P. J.
    Gruenwald, V
    Gschwend, J.
    Retz, M.
    Hartmann, A.
    Maroto Rey, J. P.
    Miller, K.
    Grimm, M. -O
    Siemer, S.
    Panic, A.
    Bergmann, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 205 - 205
  • [8] GENOMIC BIOMARKERS OF RESPONSE TO NIVOLUMAB/IPILIMUMAB AND NIVOLUMAB MONOTHERAPY IN 108 PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    DiNatale, Renzo
    Lee, Chung-Han
    Chowell, Diego
    Makarov, Vladimir
    Redzematovic, Almedina
    Murray, Samuel
    Carlo, Maria
    Voss, Martin
    Coleman, Jonathan
    Russo, Paul
    Motzer, Robert
    Chan, Timothy
    Hakimi, Ari
    JOURNAL OF UROLOGY, 2019, 201 (04): : E346 - E346
  • [9] REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
    Vauchier, Charles
    Auclin, Edouard
    Barthelemy, Philippe
    Carril-Ajuria, Lucia
    Ryckewaert, Thomas
    Borchiellini, Delphine
    Castel-Ajgal, Zahra
    Bennamoun, Mostefa
    Campedel, Luca
    Thiery-Vuillemin, Antoine
    Coquan, Elodie
    Crouzet, Laurence
    Berdah, Jean-Francois
    Chevreau, Christine
    Ratta, Raffaele
    Flechon, Aude
    Lefort, Felix
    Albiges, Laurence
    Gross-Goupil, Marine
    Vano, Yann-Alexandre
    Thibault, Constance
    Oudard, Stephane
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [10] PHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M.
    Rini, B. I.
    McDermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M.
    Sharma, P.
    Kollmannsberger, C. K.
    Heng, D.
    Shen, Y.
    Kurland, J.
    Spratlin, J.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2014, 25
12345